Skip to contentI
Insight Molecular Diagnostics Inc.
I
IMDXInsight Molecular Diagnostics Inc. Q3 2021 · 10-Q
Revenue$984.00K$984.00K+77.3% vs Q3 2020 Net Income-$13.80M-$13.80MN/M vs Q3 2020 EPS Diluted-$0.15-$0.15N/M vs Q3 2020 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Insight Molecular Diagnostics Inc. · CIK 1642380 · Engraved from SEC EDGAR
Operating Cash Flowderived-$10,983,000N/M Free Cash Flowderived-$11,377,000N/M Margins · derivedGross margin-88.0%−79.7 pt vs Q3 2020
Operating margin-1382.5%−257.5 pt vs Q3 2020
Net margin-1402.4%−180.3 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 9, 2021 · 40 d after period end